1. Introduction {#sec1}
===============

According to the 2014 WHO classification, mature cystic teratomas (MCT) constitute approximately 20% of all ovarian neoplasms also being the commonest germ cell tumor \[[@B1]\]. They are tumors which can form mature tissues derived from ectoderm, mesoderm, and endoderm and are usually cystic \[[@B2]\]. The majority of these tumors are benign with malignant transformation being rare and reported in only 1-2% of cases \[[@B3], [@B4]\]. Among the malignant transformations, squamous cell carcinoma and adenocarcinoma are the most commonly reported \[[@B5]\]. Urothelial carcinomas arising in an MCT is rare \[[@B3]--[@B9]\]. This is a report of such a case in a 50-year-old lady.

2. Case Report {#sec2}
==============

A 50-year-old lady presented to the Pondicherry Institute of Medical Sciences Hospital at Puducherry, India, with a complaint of acute abdominal pain. Contrast enhanced computed tomography (CECT) demonstrated the presence of bilateral ovarian mature cystic teratomas. Contrast enhancement within the right ovarian cyst suggested the possibility of malignant transformation ([Figure 1](#fig1){ref-type="fig"}). Tumor marker carbohydrate antigen- (CA-) 125 was 27 IU/mL (normal \<35 IU/mL). She underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy.

Gross examination showed the right ovary to be cystic and measured 12cms in diameter and is predominantly smooth except for an area of 3cm^2^ which had blunt pale soft projections ([Figure 2](#fig2){ref-type="fig"}). The left ovary was grossly normal measuring 3cms in greatest diameter.

Microscopically the left and right ovary showed various mature tissues including bronchial mucosa, apocrine glands, cartilage, and skin with adnexal structures. The microscopy of the soft pale projections of the right ovary had papillary structures with fibrovascular cores which were lined by transitional epithelium exhibiting nuclear pleomorphism, hyperchromatism, and increased mitotic activity ([Figure 3](#fig3){ref-type="fig"}). There was evidence of invasion of the ovarian stroma by nests of malignant epithelial cells ([Figure 4](#fig4){ref-type="fig"}). The inked ovarian capsular surface was free of tumor. Immunohistochemistry (IHC) of the urothelial carcinoma showed cytoplasmic and membrane positivity for Uroplakin II ([Figure 5](#fig5){ref-type="fig"}). A diagnosis of ovarian cystic teratoma with primary invasive urothelial carcinoma (TNM stage pT1aNxMx) was made based on the Pathological Stage Classification by the American Joint Committee on Cancer (AJCC) 8^th^ edition \[[@B10]\].

The patient was reviewed till 3 months following surgery and follow-up CECT revealed no evidence of recurrent tumor in the abdomen and pelvis.

3. Discussion {#sec3}
=============

Urothelial carcinomas complicating an MCT is rare and only 7 such cases have been reported in literature so far \[[@B3]--[@B9]\]. The diagnosis of primary invasive urothelial carcinoma in the present case was made by morphology and immunohistochemically demonstrating Uroplakin II in the malignant cells.

A review of the salient features of the 7 prior cases and that of the present patient is presented in [Table 1](#tab1){ref-type="table"} \[[@B3]--[@B9]\].

Studies by Al-Rayyan et al. and Kikkawa et al. showed varying number of patients with malignant transformation of an ovarian MCT who were postmenopausal or premenopausal thus indicating that menopause itself does not pose as a risk factor for malignant transformation in an MCT \[[@B4], [@B11]\]. Older age group ( \>45 years), elevated levels of CA-125 (35 IU/mL), preoperative tumor size (\>9.9cm), and characteristic imaging findings were noted as independent risk factors for malignant transformation of an MCT \[[@B3], [@B11], [@B12]\]. The present case differed in that no elevation of CA-125 (27 IU/mL) was noted unlike majority of the previous cases \[[@B3]--[@B9]\].

The pathogenesis of urothelial carcinoma in an MCT was hypothesized in two studies from Korea which noted the presence of normal urothelium adjacent to the urothelial carcinoma hence suggesting that prolonged and persistent irritation of the urothelium by lipid material induced the secondary carcinomatous change \[[@B7], [@B9]\].

Lee et al and Dasgupta et al. stated the importance of differentiating the urothelial carcinoma arising in an MCT from a primary transitional cell carcinoma of the ovary (TCC-O) which is a subtype of surface epithelial tumors \[[@B6], [@B7]\]. Lee stated that the urothelial carcinoma of the urinary tract expressed Uroplakin III but is negative for WT1. On the contrary TCC-O is negative for Uroplakin III and positive for WT1 \[[@B7]\]. Smith et al. and Li et al. in 2014 showed that Uroplakin II is a more sensitive immunohistochemical marker than Uroplakin III for detecting urothelial carcinoma of the urinary tract \[[@B13], [@B14]\]. In the present case the urothelial carcinoma arising in the MCT showed cytoplasmic and membrane positive staining for Uroplakin II suggesting its origin from the urothelium of the teratoma. The possibility of metastatic deposits from a primary urinary tract carcinoma was ruled out by radiological evaluation showing no lesion in the urinary system. Hence a diagnosis of primary invasive urothelial carcinoma arising in a mature cystic teratoma of the ovary was made.

4. Conclusion {#sec4}
=============

Malignant transformation in an MCT is a rare complication but must be suspected in high risk cases of age \> 45 years, size larger than 9cm, and elevated tumor marker CA-125 levels. Urothelial carcinomas arising in an MCT of ovary is a rare occurrence and to the best of our knowledge this is the eighth such case reported in literature.
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![Contrast enhanced computed tomography (CE-CT) image showing cystic right ovary with arrow pointing to enhanced solid densities within the cyst.](CRIPA2018-6892783.001){#fig1}
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![High power view of histomorphology of urothelial carcinoma (H&E 400X magnification).](CRIPA2018-6892783.003){#fig3}

![Low power view of urothelial carcinoma with arrow pointing at nests of invasive malignant epithelial cells in ovarian stroma (H&E 10X magnification).](CRIPA2018-6892783.004){#fig4}

![High power view of tumor cells showing cytoplasmic and membranous positivity for Uroplakin II (IHC 40X magnification).](CRIPA2018-6892783.005){#fig5}

###### 

Reported cases of urothelial carcinoma arising from mature cystic teratoma of ovary.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                             Age   Menopause   Symptoms                                   Tumor size (cm)   Laterality   Tumor marker elevated   FIGO stage   Primary surgery            Further Treatment                      Follow-up
  --------------------------------- ----- ----------- ------------------------------------------ ----------------- ------------ ----------------------- ------------ -------------------------- -------------------------------------- --------------
  Lee et al, 1999 \[[@B9]\]         67    Post        Voiding difficulty, lower abdominal pain   14x7x5            Left         CA-125\                 IC           TAH+BSO+omentectomy        Chemotherapy; carboplatin, etoposide   NED 5 months
                                                                                                                                CA 19-9                                                                                                

                                                                                                                                                                                                                                       

  Kido et al, 1999 \[[@B5]\]        48    NA          NA                                         NA                NA           NA                      IC           NA                         NA                                     NDA

                                                                                                                                                                                                                                       

  Yamaguchi et al, 2007 \[[@B3]\]   48    NA          Abdominal mass                             20                Left         CA-125\                 IA           TAH+BSO+omentectomy                                               NED 10y
                                                                                                                                CEA\                                                                                                   
                                                                                                                                SCC                                                                                                    

                                                                                                                                                                                                                                       

  Rayyan et al, 2009 \[[@B4]\]      45    Pre         Pain, bleeding                             8                 Left         NA                      IA           LSO                        Surgical Staging                       NED\>5 y

                                                                                                                                                                                                                                       

  Lee & Lee, 2010 \[[@B7]\]         52    Pre         Abdominal mass                             22x19x5           Right        NA                      IA           RSO                        NA                                     NED 15 mo

                                                                                                                                                                                                                                       

  Chuang et al, 2015 \[[@B8]\]      54    Post        Abdominal mass                             20x13x21          Right        CA-125,\                IA           TAH+BSO+omentectomy+BPLA   None                                   NED 8 mo
                                                                                                                                CA 19-9                                                                                                

                                                                                                                                                                                                                                       

  Dasgupta et al, 2015 \[[@B6]\]    50    Post        Pain and abdominal swelling                11x9x6            Right        CA-125                  IA           TAH+BSO                    None                                   NED

                                                                                                                                                                                                                                       

  Present case                      50    NA          Pain                                       12x8x5            Right        \-                      IA           TAH+BSO                    None                                   NED 3 mo
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BPLA= bilateral pelvic lymphadenectomy, BSO= bilateral salpingo-oophorectomy, FIGO= International Federation of Obstetrics and Gynecology, LSO= left salpingo-oophorectomy, NA= not available, NDA=no data available, NED=no evidence of disease, RSO= right salpingo-oophorectomy, and TAH= total abdominal hysterectomy.
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